Medisys looks to US with safety needle deal with Smiths
This article was originally published in Clinica
Executive Summary
Shares in UK safety needle company Medisys rose 8% to £0.72 ($1) on news that Smiths Medical is to become its exclusive co-marketing partner for its Future range of products in North America, Japan and the UK. Medisys has received an initial $1 million cash payment and the deal allows for a further $3.95 million in relation to commercial launches.